Topic summary

Retatrutide phase 2 in type 2 diabetes: the Lancet paper

Compounds › Retatrutide randomised trial preprint effect size retatrutide TRIUMPH programme Solved Closed

This is a generated summary. It shows the 5 most-liked posts from a topic of 17, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.brobergTL217 Apr 2025#3

Picking up the opening post: that is the part I would want checked first.

Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early evidence base and this page will say so until it changes.

I would be glad to be shown a cleaner way of putting this.

21 likes 15mo

orbitrap_olaTL3Mass spectrometrist Solution26 Apr 2025#4

s.vanhecke, post #1: On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. Asking about retatrutide phase 2 in type on behalf of the question I keep seeing asked badly, including by me. Framed properly it is answerable. Framed the usual way it is not, and that is most of why the… Go to post

The evidence status here should be stated in the first line of any post about it rather than the last. Everything is phase 2 or earlier, and a reader arriving from a search will not know that unless somebody says so.

A single observation, in a thread that deserves better than single observations.

7 likes in reply to #1 15mo

dr_okonkwoTL4 Moderator24 May 2025#8

n.broberg, post #3: Picking up the opening post: that is the part I would want checked first. Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early evidence base and this page will say so until it changes. I would be glad to be shown a cleaner way of… Go to post

Glycaemic effects improved rather than worsened in the diabetes work despite the glucagon component, which is the observation that resolves the apparent paradox. It is worth understanding that mechanism before repeating either half of it.

Happy to be corrected if someone holds better data than mine.

29 likes in reply to #3 14mo

c.correiaTL212 Jun 2025#11

Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.

I would call that likely rather than established.

31 likes 14mo

sa.okonkwoTL211 Jul 2025#16

k.asante, post #9: That is clearer than the version I had in my head. Thank you. Go to post

Dose-response in the phase 2 obesity work was clear across the studied range, with no obvious plateau within it. Extrapolating beyond the highest studied dose from that is exactly the reasoning trials are designed to prevent.

22 likes in reply to #9 13mo

Read the full topic (17 posts)

This topic was closed 120 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. A follow-up question about retatrutide phase 2 obesity paper that I did not know to…	+19	23	16k	2d
Why retatrutide discussion here is more cautious than elsewhere Compounds › Retatrutide randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. A question about retatrutide discussion that I think…	+7	12	7.7k	2mo
About the Retatrutide category Compounds › Retatrutide retatrutide TRIUMPH programme randomised trial Pinned Wiki Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…		4	12k	2y
Second pass at: Triple agonism: additive, synergistic, or neither? Compounds › Retatrutide TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…	+114	120	1.4k	10mo
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…	+65	71	4.6k	13mo

Related topics — sharing the tags randomised trial, preprint, effect size

Topic	Participants	Replies	Views	Activity
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Pharmacology › Receptor biology retatrutide amylin analogues semaglutide Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. A narrow question about…	+57	63	1k	6mo
[2026 update] Conference abstracts as evidence: the weakest common citation Evidence › Preprints needs a source effect size preprint risk of bias Closed Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Reading an unrefereed manuscript properly, and asking whether I am doing it…		2	48k	7mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on Compounds › Retatrutide retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Glucagon receptor…		4	3.7k	10mo
Oral versus injectable exposure: comparing apples to a different fruit Compounds › Oral incretins oral semaglutide SOUL trial PIONEER programme randomised trial Oral versus injectable exposure: comparing apples to a different fruit — setting out what I have, and where I think it stops being reliable. Something about oral versus injectable exposure does not reconcile…	+19	23	332	8mo
SNAC and the mechanism of oral peptide absorption Compounds › Oral incretins orforglipron randomised trial PIONEER programme oral semaglutide On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. A comparison question rather than a question about one compound. Two things in the same…	+13	17	14k	17mo